About StemSynergy

StemSynergy (SSTI) is a biotechnology company focused on the discovery and development of novel therapeutics that target mechanisms fundamental to cancer, such as Wnt, Notch, and Myc signaling. We identify drug targets in these pathways that provide greater efficacy and minimal toxicity.

We have one patent awarded and three patents pending for our breakthrough technologies. Our robust preclinical pipeline includes six innovative therapeutic agents in development.

With a multi-pronged scientific approach and a number of agents targeting these pathways, SSTI is well positioned to address critical unmet needs in cancer treatment.